OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Present at the 2017 Marcum Microcap Conference

Download PDF

NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the 2017 Marcum Microcap Conference, taking place June 15-16 at the Grand Hyatt New York Hotel.

Ohr Pharmaceutical Presentation Details
Date: Thursday, June 15
Time: 2:30pm Eastern Time
Location: Winter Garden, Conference Level
Webcast:     http://wsw.com/webcast/marcum5/ohrp

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc.   
Investor Relations    
888-388-2327     
ir@ohrpharmaceutical.com   

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com

Primary Logo

Source: Ohr Pharmaceutical, Inc.